---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338020"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2026-08-06T20:11:42+00:00"
generated_at: "2026-08-06T20:16:01.844812+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics Q2 2026 net income $1.5M; cash runway to Q3 2028

## Summary
- Q2 2026 net income of $1.5M ($0.01 basic EPS) vs net loss of $30.5M in Q2 2025; revenue $1.1M, down from $2.8M.
- Cash $50.8M expected to fund operations into Q3 2028.
- RG6501 (OpRegen) Phase 1/2a 3-year data showed sustained BCVA gains and retinal structure restoration in Cohort 4.
- COR1 corneal endothelial cell therapy program advanced to in-vivo animal testing; initial data expected in 2026.
- Established Scientific Advisory Board with Joachim Fruebis, PhD as founding member.

## SEC filing metadata
- accession: 0001193125-26-338020
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2026-08-06T20:11:42+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/0001193125-26-338020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/lctx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338020
- JSON: https://secwatch.observer/filing/0001193125-26-338020.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.